A phase 3 trial of pirfenidone in patients with idiopathic pulmonary fibrosis.
Open accessThe DOI matches its Crossref record; 27 of the 27 references it cites were found in a registry or an index.
Abstract
BACKGROUND: In two of three phase 3 trials, pirfenidone, an oral antifibrotic therapy, reduced disease progression, as measured by the decline in forced vital capacity (FVC) or vital capacity, in patients with idiopathic pulmonary fibrosis; in the third trial, this end point was not achieved. We sought to confirm the beneficial effect of pirfenidone on disease progression in such patients. METHODS: In this phase 3 study, we randomly assigned 555 patients with idiopathic pulmonary fibrosis to receive either oral pirfenidone (2403 mg per day) or placebo for 52 weeks. The primary end point was the change in FVC or death at week 52. Secondary end points were the 6-minute walk distance, progression-free survival, dyspnea, and death from any cause or from idiopathic pulmonary fibrosis. RESULTS: In the pirfenidone group, as compared with the placebo group, there was a relative reduction of 47.9% in the proportion of patients who had an absolute decline of 10 percentage points or more in the percentage of the predicted FVC or who died; there was also a relative increase of 132.5% in the proportion of patients with no decline in FVC (P<0.001). Pirfenidone reduced the decline in the 6-minute walk distance (P=0.04) and improved progression-free survival (P<0.001). There was no significant between-group difference in dyspnea scores (P=0.16) or in rates of death from any cause (P=0.10) or from idiopathic pulmonary fibrosis (P=0.23). However, in a prespecified pooled analysis incorporating results from two previous phase 3 trials, the between-group difference favoring pirfenidone was significant for death from any cause (P=0.01) and from idiopathic pulmonary fibrosis (P=0.006). Gastrointestinal and skin-related adverse events were more common in the pirfenidone group than in the placebo group but rarely led to treatment discontinuation. CONCLUSIONS: Pirfenidone, as compared with placebo, reduced disease progression, as reflected by lung function, exercise tolerance, and progression-free survival, in patients with idiopathic pulmonary fibrosis. Treatment was associated with an acceptable side-effect profile and fewer deaths. (Funded by InterMune; ASCEND ClinicalTrials.gov number, NCT01366209.).
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Idiopathic pulmonary fibrosis (IPF), the prototype of fibrotic ILDs, carries a prognosis of 3–5 years survival after diagnosis when untreated. Two anti-fibrotic medications (nintedanib and pirfenidone) have been shown to reduce the rate of forced vital capacity (FVC) decline and slow disease progression in patients with a definite usual interstitial pneumonia (UIP) pattern and with a probable UIP pattern on high resolution CT (HRCT).(191–193)”
From Consensus document for the selection of lung transplant candidates: An update from the International Society for Heart and Lung Transplantation. (2021) · cites this paper as [191]
In the citing paper
“However, both have significant adverse effects and neither completely arrest the decline in lung function.”
From Emerging pharmacological options in the treatment of idiopathic pulmonary fibrosis (IPF) (2024) · cites this paper as [13]
In the citing paper
“In three trials with doses that reached 2403 mg/day, pirfenidone effectively reduced FVC decline although had variable reductions in overall mortality and IPF-related mortality [12,13].”
From Emerging pharmacological options in the treatment of idiopathic pulmonary fibrosis (IPF) (2024) · cites this paper as [13]
In the citing paper
“Reported adverse events in the present trial were generally acceptable and largely consistent with events previously reported by participants in the placebo arms of randomized controlled trials in IPF [45,46].”
From Senolytics in idiopathic pulmonary fibrosis: Results from a first-in-human, open-label, pilot study (2019) · cites this paper as [45]
In the citing paper
“FVC is the gold-standard metric for assessing the lung function of patients with IPF and response to therapeutic intervention33–35.”
From A generative AI-discovered TNIK inhibitor for idiopathic pulmonary fibrosis: a randomized phase 2a trial (2025) · cites this paper as [35]
9 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
Miller, M. R., Hankinson, J., Brusasco, V., Burgos, F., Casaburi, R., Coates, A., Crapo, R., Enright, P., van der Grinten, C. P. M., Gustafsson, P., et al. (2005) · European Respiratory Journal · doi:10.1183/09031936.05.00034805 · Cited by 15,627
Raghu, G., Collard, H. R., Egan, J. J., Martinez, F. J., Behr, J., Brown, K. K., Colby, T. V., Cordier, J.-F., Flaherty, K. R., Lasky, J. A., et al. (2011) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.2009-040gl · Cited by 7,186
Self-citationA sharper Bonferroni procedure for multiple tests of significance
HOCHBERG, Y. (1988) · Biometrika · doi:10.1093/biomet/75.4.800 · Cited by 4,829
Pirfenidone in patients with idiopathic pulmonary fibrosis (CAPACITY): two randomised trials
Noble, P. W., Albera, C., Bradford, W. Z., Costabel, U., Glassberg, M. K., Kardatzke, D., King, T. E., Lancaster, L., Sahn, S. A., Szwarcberg, J., et al. (2011) · The Lancet · doi:10.1016/s0140-6736(11)60405-4 · Cited by 2,154
Self-citationDouble-blind, Placebo-controlled Trial of Pirfenidone in Patients with Idiopathic Pulmonary Fibrosis
Azuma, A., Nukiwa, T., Tsuboi, E., Suga, M., Abe, S., Nakata, K., Taguchi, Y., Nagai, S., Itoh, H., Ohi, M., et al. (2005) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.200404-571oc · Cited by 954
Pirfenidone in idiopathic pulmonary fibrosis
Taniguchi, H., Ebina, M., Kondoh, Y., Ogura, T., Azuma, A., Suga, M., Taguchi, Y., Takahashi, H., Nakata, K., Sato, A., et al. (2010) · European Respiratory Journal · doi:10.1183/09031936.00005209 · Cited by 946
Pirfenidone in idiopathic pulmonary fibrosis: Figure 1–
Swigris, J., & Fairclough, D. (2010) · European Respiratory Journal · doi:10.1183/09031936.00071710 · Cited by 799
Self-citationChanges in Clinical and Physiologic Variables Predict Survival in Idiopathic Pulmonary Fibrosis
Collard, H. R., King, T. E., Bartelson, B. B., Vourlekis, J. S., Schwarz, M. I., & Brown, K. K. (2003) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.200211-1311oc · Cited by 764
Self-citationThe Clinical Course of Patients with Idiopathic Pulmonary Fibrosis
Martinez, F. J., Safrin, S., Weycker, D., Starko, K. M., Bradford, W. Z., King, T. E., Flaherty, K. R., Schwartz, D. A., Noble, P. W., Raghu, G., et al. (2005) · Annals of Internal Medicine · doi:10.7326/0003-4819-142-12_part_1-200506210-00005 · Cited by 622
Self-citationKing, T. E., Albera, C., Bradford, W. Z., Costabel, U., Hormel, P., Lancaster, L., Noble, P. W., Sahn, S. A., Szwarcberg, J., Thomeer, M., et al. (2009) · The Lancet · doi:10.1016/s0140-6736(09)60551-1 · Cited by 531
Self-citation
Cited by
Items 2,601–2,700 of 3,967
Podolanczuk, A. J., & Aronson, K. I. (2024) · European Respiratory Journal · doi:10.1183/13993003.00067-2024 · Cited by 4
Tao, H., Lv, Q., Zhang, J., Chen, L., Yang, Y., & Sun, W. (2024) · Stem Cells International · doi:10.1155/2024/3429565 · Cited by 5
Sagmeister, P., Rosch, S., Fengler, K., Kresoja, K., Gori, T., Thiele, H., Lurz, P. C., Burkhoff, D., & Rommel, K. (2024) · Experimental Physiology · doi:10.1113/ep091776 · Cited by 6
Xu, F., Tong, Y., Yang, W., Cai, Y., Yu, M., Liu, L., & Meng, Q. (2024) · Respiratory Research · doi:10.1186/s12931-024-02738-w · Cited by 5
Identification of CFH and FHL2 as biomarkers for idiopathic pulmonary fibrosis
Liu, X., Yang, M., Li, J., Liu, H., Dong, Y., Zheng, J., & Huang, Y. (2024) · Frontiers in Medicine · doi:10.3389/fmed.2024.1363643 · Cited by 6
“Only two recommended drugs (nintedanib and pirfenidone) that have been approved for IPF but can only delay the decline in lung function and cannot stop the progression of the disease (11, 12).”
BackgroundSöllner, J. F., Bentink, S., Heßlinger, C., Leonard, T. B., Neely, M. L., Patel, N. M., Schlange, T., Todd, J. L., Vinisko, R., Salisbury, M. L., et al. (2024) · Lung · doi:10.1007/s00408-024-00742-x · Cited by 4
Dong, Z., Wang, X., Wang, P., Bai, M., Wang, T., Chu, Y., & Qin, Y. (2024) · Advanced Biology · doi:10.1002/adbi.202400297 · Cited by 6
What Is on the Horizon for Treatments in Idiopathic Pulmonary Fibrosis?
Moua, T., Baqir, M., & Ryu, J. H. (2024) · Journal of Clinical Medicine · doi:10.3390/jcm13216304 · Cited by 9
“While two antifibrotic medications (nintedanib and pirfenidone) [2,3] have been shown to slow disease progression and are currently in use, a significant need remains for more effective agents that may prevent loss of lung function and even reverse fibrosis.”
BackgroundYuan, X., Chen, Y., Liu, S., Shu, Q., Duan, X., Tang, L., Peng, L., Zhou, S., Wu, C., Zhao, J., et al. (2024) · Therapeutic Advances in Respiratory Disease · doi:10.1177/17534666241292507 · Cited by 5
Bongiolatti, S., Salvicchi, A., Rosi, E., Bargagli, E., Mugnaini, G., Gonfiotti, A., Lavorini, F., Spagnolo, P., Dell’Amore, A., Rea, F., et al. (2024) · Life · doi:10.3390/life14111506 · Cited by 11
“Anti-fibrotic therapies are, nowadays, the mainstay of the treatment of IPF [12], but only few retrospective studies from Asia have suggested a potential protective role for perioperative AFT [15,16,25,26].”
Ficolin-1 ameliorates pulmonary fibrosis via directly binding to TGF-β1
Gao, P., Lu, Y., Tang, K., Wang, W., Wang, T., Zhu, Y., Zhao, J., & Mao, Y. (2024) · Journal of Translational Medicine · doi:10.1186/s12967-024-05894-1 · Cited by 7
Anti-Inflammatory Effects of Aptamin C in Pulmonary Fibrosis Induced by Bleomycin
Shin, S., Jo, H., Agura, T., Jeong, S., Ahn, H., Pang, S., Lee, J., Park, J.-H., Kim, Y., & Kang, J. S. (2024) · Pharmaceuticals · doi:10.3390/ph17121577 · Cited by 4
“Medications such as antifibrotics (e.g., pirfenidone, nintedanib) are used to inhibit the progression of lung fibrosis [18–20].”
Qiu, W., Wang, Q., Zhang, Y., Cao, X., Zhao, L., Cao, L., Sun, Y., Yang, F. L., Guo, Y., Sui, Y., et al. (2024) · Laboratory Investigation · doi:10.1016/j.labinv.2024.102210 · Cited by 4
Telomeropathies in Interstitial Lung Disease and Lung Transplant Recipients
Southern, B. D., & Gadre, S. K. (2025) · Journal of Clinical Medicine · doi:10.3390/jcm14051496 · Cited by 11
“There are currently two approved therapies for IPF (pirfenidone, nintedanib) [68,69] and one approved therapy for progressive pulmonary fibrosis (nintedanib) [70].”
Ma, J., Ding, L., Zang, X., Yang, Y., Zhang, W., Li, X., Zhao, D., Zhang, Z., Wang, Z., Zhao, L., et al. (2025) · Journal of Inflammation Research · doi:10.2147/jir.s515286 · Cited by 5
Pirfenidone combined with UC-MSCs reversed bleomycin-induced pulmonary fibrosis
Xu, J., Abudureheman, Z., Gong, H., Zhong, X., Xue, L., Zou, X., & Li, L. (2025) · Scientific Reports · doi:10.1038/s41598-025-14286-4 · Cited by 6
Concomitant Idiopathic Pulmonary Fibrosis and Lung Cancer: An Updated Narrative Review
Czyżak, B., & Majewski, S. (2025) · Advances in respiratory medicine · doi:10.3390/arm93040031 · Cited by 9
“Some large retrospective studies support this statement, which will be discussed in more detail in the different paragraphs of this review [11,12,23,135,136].”
Drug development for chronic lung disease ‐ Mission impossible?
Ask, K., & Kolb, M. R. J. (2014) · Respirology · doi:10.1111/resp.12445 · Cited by 4
Where do we go from here? Clinical drug development in idiopathic pulmonary fibrosis
Collard, H. R. (2015) · European Respiratory Journal · doi:10.1183/09031936.00237114 · Cited by 4
Maher, T. M., Piper, A. J., Song, Y., Restrepo, M. I., & Eves, N. D. (2015) · Respirology · doi:10.1111/resp.12532 · Cited by 4
Idiopathic pulmonary fibrosis: securing a confident diagnosis for every patient
Jones, M. G., Walsh, S. L. F., Jones, K. D., & Richeldi, L. (2016) · European Respiratory Journal · doi:10.1183/13993003.00265-2016 · Cited by 4
The Keys to Making a Confident Diagnosis of IPF
Wadhwa, A., & Flaherty, K. R. (2013) · Humana Press eBooks · doi:10.1007/978-1-62703-682-5_5 · Cited by 4
Kocher, E., Rendon, K. J., Kesler, D. O., et al. (2016) · Journal of Health Care for the Poor and Underserved · doi:10.1353/hpu.2016.0193 · Cited by 4
Treatment doses in idiopathic pulmonary fibrosis: The devil is in the detail
Wells, A. U., & Antoniou, K. M. (2017) · Respirology · doi:10.1111/resp.13182 · Cited by 4
Wencel, M. L., Haselkorn, T., Limb, S. L., Stauffer, J. L., Morgenthien, E. A., Raimundo, K., & LaCamera, P. P. (2018) · Pulmonary Therapy · doi:10.1007/s41030-018-0056-8 · Cited by 4
Caro, F. M., Alberti, M. L., Campins, F., Enghelmayer, J. I., Fernández, M. E., Lancellotti, D., Papucci, T., Sebastiani, J. A., & Paulín, F. (2018) · Archivos de Bronconeumología · doi:10.1016/j.arbres.2018.06.014 · Cited by 5
Steiner, C. A., & Higgins, P. (2018) · Springer eBooks · doi:10.1007/978-3-319-90578-5_23 · Cited by 6
Han, X., Li, F., Wen, Z., Ma, Y., Wang, L., & Cheng, Z. (2019) · Clinical and Experimental Pharmacology and Physiology · doi:10.1111/1440-1681.13078 · Cited by 5
Assessing quality of life of idiopathic pulmonary fibrosis patients: the INSTAGE study
Suárez-Cuartín, G., & Molina‐Molina, M. (2019) · Breathe · doi:10.1183/20734735.0016-2019 · Cited by 4
“Nevertheless, both nintedanib and pirfenidone treatments were approved by the US Food and Drug Administration for IPF, as they showed a significant effect on FVC decline when compared to placebo [2, 8, 9].”
BackgroundCreamer, A. W., & Barratt, S. L. (2019) · Breathe · doi:10.1183/20734735.0002-2019 · Cited by 4
“For idiopathic pulmonary fibrosis (IPF), the most common and fatal ILD, antifibrotic therapies (nintedanib [1] and pirfenidone [2]) have been shown to slow rate of progression, but the disease remains incurable.”
BackgroundHermansky–Pudlak syndrome with interstitial lung disease: A holistically worked up couplet
Joshi, J. M., Gupta, A., Utpat, K. V., et al. (2019) · Lung India · doi:10.4103/lungindia.lungindia_258_18 · Cited by 4
Mammographic Density: Intersection of Advocacy, Science, and Clinical Practice
Tossas, K. Y., Shalabi, S., Jones, V., Keely, P. J., Conklin, M. W., Eliceiri, K. W., Winn, R. A., Sistrunk, C., Geradts, J., Miranda‐Carboni, G. A., et al. (2019) · Current Breast Cancer Reports · doi:10.1007/s12609-019-00316-4 · Cited by 5
Magnetic Resonance in Crohn Disease
Rimola, J., & Capozzi, N. (2019) · Magnetic Resonance Imaging Clinics of North America · doi:10.1016/j.mric.2019.08.004 · Cited by 4
Practice guidelines for interstitial lung diseases: Widening the reach
Montesi, S. B. (2020) · Lung India · doi:10.4103/lungindia.lungindia_487_20 · Cited by 4
Holland, A. E., Dowman, L., & Smallwood, N. (2020) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.202007-2775ed · Cited by 5
Sakamoto, S., Shimizu, H., Isshiki, T., Nakamura, Y., Kurosaki, A., Isobe, K., & Homma, S. A. (2020) · The Clinical Respiratory Journal · doi:10.1111/crj.13292 · Cited by 6
Nunes, F., Pastré, J., Brown, A. W., Shlobin, O. A., King, C. S., Weir, N. A., & Nathan, S. D. (2021) · PubMed Central · doi:10.36141/svdld.v38i1.9258 · Cited by 4
Self-citationInhibitory effects of somatostatin analogue in bleomycin-induced pulmonary fibrosis
Hosono, T., Bando, M., Mizushina, Y., Sata, M., Hagiwara, K., & Sugiyama, Y. (2021) · Experimental Lung Research · doi:10.1080/01902148.2021.1916650 · Cited by 4
Camp, R. L., Smith, M. L., Larsen, B. T., Roden, A. C., Farver, C. F., Moreira, A. L., Attanoos, R. L., Pillappa, R., Sansano, I., Fabro, A. T., et al. (2021) · BMC Pulmonary Medicine · doi:10.1186/s12890-021-01522-6 · Cited by 3
Management of fibrotic hypersensitivity pneumonitis
Mullin, M. L. L., Churg, A., & Ryerson, C. J. (2022) · Current Opinion in Pulmonary Medicine · doi:10.1097/mcp.0000000000000904 · Cited by 5
Correlating SFTPC gene variants to interstitial lung disease in Egyptian children
Abdelmegeid, A. K., Refeat, M. M., Ashaat, E. A., El‐Kamah, G. Y., El-Saiedi, S. A., El-Falaki, M. M., Ruby, M. O. E., & Amr, K. S. (2022) · Journal of Genetic Engineering and Biotechnology · doi:10.1186/s43141-022-00399-0 · Cited by 4
Cano-Jiménez, E., Ortíz, A. D. R., Villar, A., Rodríguez‐Nieto, M. J., Ramón, A., & Armengol, S. (2022) · Respiratory Research · doi:10.1186/s12931-022-02154-y · Cited by 5
Banerjee, T., Das, M., & Mitra, K. (2022) · Biomedicine · doi:10.51248/.v42i5.1996 · Cited by 5
Role of TGF-β Signaling in Coronavirus Disease 2019
Chen, J., Wu, W., Wang, W., Tang, Y., & Lan, H.-Y. (2022) · Integrative Medicine in Nephrology and Andrology · doi:10.4103/2773-0387.348713 · Cited by 6
Contemporary Concise Review 2022: Interstitial lung disease
Smith, D. J. F., & Jenkins, G. R. (2023) · Respirology · doi:10.1111/resp.14511 · Cited by 6
Interstitial lung disease: a decade of progress and hope
Adegunsoye, A. (2023) · The Lancet Respiratory Medicine · doi:10.1016/s2213-2600(23)00157-1 · Cited by 4
Castelli, G., Cocconcelli, E., Bernardinello, N., Balestro, E., & Spagnolo, P. (2023) · Current Pulmonology Reports · doi:10.1007/s13665-023-00315-y · Cited by 4
Ziritaxestat and Lung Function in Idiopathic Pulmonary Fibrosis—Reply
Maher, T. M., Ford, P., & Wijsenbeek, M. S. (2023) · JAMA · doi:10.1001/jama.2023.12640 · Cited by 4
Planas‐Cerezales, L., Fabbri, L., & Pearmain, L. (2023) · Breathe · doi:10.1183/20734735.0090-2023 · Cited by 4
An up-to-date review of approved and emerging antibody therapies for idiopathic pulmonary fibrosis
Simonetti, J., Sgalla, G., & Richeldi, L. (2023) · Expert Opinion on Biological Therapy · doi:10.1080/14712598.2023.2268014 · Cited by 4
Imrecoxib attenuates bleomycin-induced pulmonary fibrosis in mice
Miao, Y., Yang, Y., Li, X., et al. (2023) · Heliyon · doi:10.1016/j.heliyon.2023.e20914 · Cited by 4
“For example, nintedanib cannot be administered to patients with liver dysfunction, and pirfenidone cannot be administered to patients with renal dysfunction [11,12].”
BackgroundJiao, T., Wang, Y., Lin, X., Song, W., Wang, L., Tapu, S. R., Xu, L., Nie, L., Zhang, Q., & Li, J. (2023) · Frontiers in Medicine · doi:10.3389/fmed.2023.1256156 · Cited by 6
Imaduddin, U., Berbudi, A., & Rohmawaty, E. (2024) · Journal of Experimental Pharmacology · doi:10.2147/jep.s439932 · Cited by 6
Yamamura, K., Hara, J., Watanabe, S., Kobayashi, T., Kase, K., Takeda, Y., Terada, N., Koba, H., Tambo, Y., Ohkura, N., et al. (2024) · Journal of Thoracic Disease · doi:10.21037/jtd-23-1443 · Cited by 6
Severe Colitis Associated with Pirfenidone Use in Idiopathic Pulmonary Fibrosis
Fiddler, C. A., Simler, N., Parfrey, H., Miremadi, A., & Chilvers, E. R. (2016) · Annals of the American Thoracic Society · doi:10.1513/annalsats.201602-118le · Cited by 4
Martino, M. D., Cobuccio, R., Bruzzese, D., Rea, G., Meoli, I., Stefanelli, F., Canora, A., Capaccio, A., Sanduzzi, A., Matarese, A., et al. (2016) · Sarcoidosis vasculitis and diffuse lung diseases · Cited by 4
AJRCCM : 100-Y ear A nniversary . Progress in Interstitial Lung Disease
Kaner, R. J., Brown, K. K., & Martínez, F. J. (2017) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.201703-0584ed · Cited by 4
Burgess, J. K., Muizer, K., Brandsma, C., & Heijink, I. H. (2018) · Molecular and translational medicine · doi:10.1007/978-3-319-98143-7_9 · Cited by 4
Pannu, J. K., Hewlett, J. C., Smith, A. B., et al. (2019) · Journal of Thoracic Disease · doi:10.21037/jtd.2019.01.44 · Cited by 4
Wuyts, W. A., Antin-Ozerkis, D. E., Huggins, J. T., LaCamera, P. P., Spagnolo, P., Vašáková, M., Wijsenbeek, M. S., Polman, B., Kirchgaessler, K.-U., & Scholand, M. B. (2019) · Respiratory Medicine · doi:10.1016/j.rmed.2019.02.021 · Cited by 5
“Three trials investigated pirfenidone: ASCEND and CAPACITY (Studies 004 and 006) [15,16].”
BackgroundAntifibrotic therapy of idiopathic pulmonary fibrosis: efficiency / safety ratio
Авдеев, С. Н., & Трушенко, Н. В. (2018) · Meditsinskiy sovet = Medical Council · doi:10.21518/2079-701x-2018-15-131-136 · Cited by 5
LaCamera, P. P., Limb, S. L., Haselkorn, T., Morgenthien, E. A., Stauffer, J. L., & Wencel, M. L. (2019) · Chronic Respiratory Disease · doi:10.1177/1479973119879678 · Cited by 4
The phosphodiesterase 4 inhibitor AA6216 suppresses activity of fibrosis-specific macrophages
Matsuhira, T., Nishiyama, O., Tabata, Y., Kurashimo, S., Sano, H., Iwanaga, T., & Tohda, Y. (2021) · Biochemistry and Biophysics Reports · doi:10.1016/j.bbrep.2021.101118 · Cited by 7
Promising new treatment targets in patients with fibrosing lung disorders
Šterclová, M., & Vasakova, M. (2014) · World Journal of Clinical Cases · doi:10.12998/wjcc.v2.i11.668 · Cited by 4
Risk Factors and Biomarkers of RA-ILD
Doyle, T. J., Dellaripa, P. F., & Rosas, I. O. (2017) · Respiratory medicine · doi:10.1007/978-3-319-68888-6_5 · Cited by 4
The TAMing of the Idiopathic Pulmonary Fibrosis Myofibroblast. One Step Closer?
Rangarajan, S., & Lee, J. S. (2018) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.201802-0222ed · Cited by 4
Ryerson, C. J., Kolb, M. R. J., Cox, G., Shapera, S., Swigris, J. J., Fell, C. D., O’Brien, M., Xue, C., Rassi, J., & Moran‐Mendoza, O. (2019) · Canadian Journal of Respiratory Critical Care and Sleep Medicine · doi:10.1080/24745332.2019.1586496 · Cited by 4
“La dur ee m ediane (fourchette) du suivi et le nombre de visites de suivi au cours des six premiers mois de traitement etaient de 10 (0,9 –34,4) mois et 3 (1-9) visites, respectivement.”
BackgroundSelf-citationUnilateral Pulmonary Fibrosis Due to Absence of Right Pulmonary Artery
Sumdani, H., Shahbuddin, Z., Farhataziz, N., & Barkley, J. M. (2019) · Cureus · doi:10.7759/cureus.5161 · Cited by 4
Therapie der systemischen Sklerose-assoziierten interstitiellen Lungenerkrankung
Prasse, A., Bonella, F., Müller‐Ladner, U., Witte, T., Hunzelmann, N., & Distler, J. H. W. (2019) · Zeitschrift für Rheumatologie · doi:10.1007/s00393-019-00724-y · Cited by 4
Do Circulating Monocytes Promote and Predict Idiopathic Pulmonary Fibrosis Progression?
Fernandez, I. E., & Kass, D. J. (2021) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.202101-0207ed · Cited by 7
FROM IDIOPATHIC FIBROSING ALVEOLITIS TO IDIOPATIC LUNGS FIBROSIS
Вячеславович, А. А., & Lesnyak, V. N. (2016) · Journal of clinical practice · doi:10.17816/clinpract7458-65 · Cited by 5
Guleria, R., Chaudhry, D., Singh, V., Kumar, R., Nangia, V., Dhar, R., Agarwal, R., Jindal, A., Madan, K., Behera, D., et al. (2022) · The Indian Journal of Chest Diseases and Allied Sciences · doi:10.5005/ijcdas-60-2-91 · Cited by 7
Interstitielle Lungenerkrankungen: Vom Bild zur Therapie
Soriano, D. B., Nattenmüller, J., Schröder, K., Schygulla, E., Jouanjan, L., Venhoff, N., Jandova, I., Stolz, D., & Frye, B. C. (2024) · Die Radiologie · doi:10.1007/s00117-024-01340-x · Cited by 4
Diagnostic Delay in Idiopathic Pulmonary Fibrosis: Where the Rubber Meets the Road
Adegunsoye, A. (2019) · Annals of the American Thoracic Society · doi:10.1513/annalsats.201812-883ed · Cited by 4
Toward Realizing the Full Potential of Registries in Interstitial Lung Disease
Durheim, M. T. (2020) · Annals of the American Thoracic Society · doi:10.1513/annalsats.202008-1077ed · Cited by 4
Yang, J., Lu, D., Sun, Y., Qiu, M., Zhao, T., Yan, B., Wang, S., Shao, Z., Wang, D., Li, T., et al. (2024) · ACS Pharmacology & Translational Science · doi:10.1021/acsptsci.4c00524 · Cited by 3
Pirfenidone to prevent fibrosis in acute respiratory distress syndrome: The PIONEER study protocol
Monti, G., Marzaroli, M., Tucciariello, M. T., Ferrara, B. G., Meroi, F., Nakhnoukh, C., Zambon, M., Borghi, G., Guarracino, F., Manazza, M., et al. (2025) · Contemporary Clinical Trials · doi:10.1016/j.cct.2025.107883 · Cited by 5
Wang, X., Zhou, T. J., Huang, S., Zhou, H., Ling, Y., Chen, T., Zhang, S., Wang, W., Wu, C., & Yin, W. (2025) · International Immunopharmacology · doi:10.1016/j.intimp.2025.114536 · Cited by 3
Majewski, S., Górska, K., Lewandowska, K. B., Martusewicz-Boros, M. M., Sobiecka, M., & Piotrowski, W. J. (2025) · Frontiers in Pharmacology · doi:10.3389/fphar.2025.1586197 · Cited by 8
Therapeutic options for patients with pulmonary hypertension and interstitial lung disease
Swisher, J. W., & Weaver, E. (2025) · Therapeutic Advances in Respiratory Disease · doi:10.1177/17534666251335815 · Cited by 3
Resolution of innate immune cells with proresolving lipid mediators in idiopathic pulmonary fibrosis
Ang, Y., Ng, A. J. K., Liao, W., Wong, K. Y. K., Wong, W. S. F., & Peh, H. Y. (2025) · Journal of Leukocyte Biology · doi:10.1093/jleuko/qiaf100 · Cited by 3
Fibrosis mechanisms and updates in potential therapeutic targets in systemic sclerosis
Han, X., Wang, X., Huang, J., & Yang, J. Y. (2025) · Seminars in Arthritis and Rheumatism · doi:10.1016/j.semarthrit.2025.152811 · Cited by 3
Zhang, X., Duan, X., Xie, X., Zhang, D., Chen, Y., Yu, R., Zhou, Y., Chu, Y., Shen, J., Cai, Y., et al. (2025) · Advanced Healthcare Materials · doi:10.1002/adhm.202501916 · Cited by 7
Wang, J. Y., & Young, L. R. (2025) · Clinics in Chest Medicine · doi:10.1016/j.ccm.2025.07.009 · Cited by 3
Seeliger, B., Ruwisch, J., Sand, J. M. B., Simões, F. B., Jessen, H., Boerner, E. B., Fuge, J., Sewald, K., Welte, T., Wendel‐Garcia, P. D., et al. (2025) · CHEST Journal · doi:10.1016/j.chest.2025.08.047 · Cited by 4
Chikasue, T., Sumikawa, H., Sumi, A., Matsumoto, K., Murotani, K., Tanoue, S., Arai, T., Shimizu, S., Inoue, Y., Johkoh, T., et al. (2025) · Japanese Journal of Radiology · doi:10.1007/s11604-025-01880-9 · Cited by 4
Orfanos, S., Deeney, B. T., Cao, G., Karmacharya, N., Ravi, A., Koziol‐White, C. J., Yang, Q., Ostrom, R. S., & Panettieri, R. A. (2025) · Respiratory Research · doi:10.1186/s12931-025-03387-3 · Cited by 7
Zhang, X., Yu, R., Duan, X., Zhang, T., Cheng, F., Pan, S., Zhou, D., Zhu, J., Cai, Y., & Sun, X. (2025) · Acta Biomaterialia · doi:10.1016/j.actbio.2025.12.038 · Cited by 5
Quantitative CT and Artificial Intelligence in Chronic Lung Disease
Oh, A. S., Humphries, S. M., Chung, A., Weigt, S. S., Brown, M., Kim, G. H. J., Lee, D., Belperio, J. A., & Goldin, J. G. (2025) · Journal of Thoracic Imaging · doi:10.1097/rti.0000000000000867 · Cited by 5
ECM-Targeted and cell-based therapies in musculoskeletal and aging-related disorders: A review
Ahn, K., & Park, H. (2026) · Technology and Health Care · doi:10.1177/09287329251414507 · Cited by 3
Emerging Therapies in Pulmonary Fibrosis
Etchingham-Coll, H., Temizel, E., Okezie-Enyioma, N., Martin, N., Kaenmuang, P., Coghlan, S., Spagnolo, P., & Chaudhuri, N. (2026) · Pulmonary Therapy · doi:10.1007/s41030-026-00349-y · Cited by 6
Wang, Y., Liu, X., Xuan, W., Huang, W., Zhu, Y., Mao, C., & Liu, Y. (2026) · Molecular Therapy · doi:10.1016/j.ymthe.2026.03.003 · Cited by 7
Shahzad, H., Afzaal, U., Saleem, F., Gul, A. H., Thummar, F. R., Murtaza, H. N., Gelan, A. A., Ahsan, M., Irfan, R., Nawaz, A., et al. (2026) · The Clinical Respiratory Journal · doi:10.1111/crj.70181 · Cited by 7
Old and emerging therapies for childhood interstitial lung disease (chILD): a systematic review
Tonazzo, V., Castaldo, R. J., Zanconato, S., Carraro, S., & Ferraro, V. A. (2026) · European Respiratory Review · doi:10.1183/16000617.0062-2025 · Cited by 4
Juan-Guardela, B. M., & Herazo-Maya, J. (2026) · American Journal of Respiratory and Critical Care Medicine · doi:10.1093/ajrccm/aamag121 · Cited by 3
Chen, Y., Hu, L., Fu, Q., et al. (2026) · Journal of Ethnopharmacology · doi:10.1016/j.jep.2026.121597 · Cited by 3
Idiopathic interstitial pneumonias in 2015: A new era
Corte, T. J., Collard, H. R., & Wells, A. U. (2015) · Respirology · doi:10.1111/resp.12559 · Cited by 3
Chambers, D. C. (2015) · Respirology · doi:10.1111/resp.12580 · Cited by 3
M264 Health And Economic Impact Of Prescribing Pirfenidone
Chaudhuri, N., & Leonard, C. (2014) · Thorax · doi:10.1136/thoraxjnl-2014-206260.445 · Cited by 3
Historical eye on IPF: a cohort study redefining the mortality scenario
Tomassetti, S., Ravaglia, C., Piciucchi, S., Ryu, J. H., Wells, A. U., Donati, L., Dubini, A., Klersy, C., Luzzi, V., Gori, L., et al. (2023) · Frontiers in Medicine · doi:10.3389/fmed.2023.1151922 · Cited by 4
“Warfarin, N (%) 36 (6) 26 (9) 10 (3) 0.”
BackgroundInfluential
Metadata
- Authors
- King, T. E., Bradford, W. Z., Castro-Bernardini, S., Fagan, E. A., Glaspole, I., Glassberg, M. K., Gorina, E., Hopkins, P. M., Kardatzke, D., Lancaster, L., Lederer, D. J., Nathan, S. D., Pereira, C. A., Sahn, S. A., Sussman, R., Swigris, J. J., & Noble, P. W.
- Affiliations
- Cedars-Sinai Medical Center (US)
- The Alfred Hospital (AU)
- University of Miami (US)
- Prince Charles Hospital (AU)
- Vanderbilt University Medical Center (US)
- Columbia University Irving Medical Center (US)
- Inova Fairfax Hospital (US)
- Universidade Federal de São Paulo (BR)
- Medical University of South Carolina (US)
- Overlook Medical Center (US)
- National Jewish Health (US)
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2014-05-29
- Volume
- 370
- Issue
- 22
- Pages
- 2083-2092
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2168666423
- Cited by
- 3,975
- References
- 27
- Citations by year
- 2026: 272 · 2025: 303 · 2024: 371 · 2023: 315 · 2022: 339 · 2021: 412 · 2020: 343 · 2019: 310 · 2018: 335 · 2017: 319 · 2016: 288 · 2015: 279 · 2014: 76
- FWCI
- 256.80
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- UNIFESP Institutional Repository (Universidade Federal de São Paulo) (submittedVersion)
- Topics
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Chronic Obstructive Pulmonary Disease (COPD) Research
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Pulmonary Hypertension Research and Treatments
- Keywords
- pirfenidone, idiopathic pulmonary fibrosis, antifibrotic therapy, forced vital capacity decline, disease progression, mortality, progression-free survival, 6-minute walk distance, dyspnea, gastrointestinal adverse effects, cutaneous adverse events, exercise tolerance, lung function decline, safety and tolerability
- MeSH terms
- Administration, Oral, Adult, Aged, Aged, 80 and over, Antifibrinolytic Agents, Double-Blind Method, Enzyme Inhibitors, Female, Humans, Male, Middle Aged, Pyridones, Vital Capacity, Treatment Outcome, Disease Progression, Idiopathic Pulmonary Fibrosis
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.